Abstract
Background and objective
This case study describes the pharmacokinetic and pharmacodynamic modelling undertaken during the development programme for UK-279,276 (neutrophil inhibitory factor), focusing on the transition from early empirical-based models to a final mechanistic-based model. UK-279,276 binds to the CD11b/CD18 (MAC-1) on neutrophils and was under development for the treatment of ischaemic stroke.
Methods
The aims, data, models, results and value-to-drug development processs across four stages of model development are described: (i) the validation of the pharmacokinetic assay; (ii) the development and application of an empirical patient pharmacokinetic/pharmacodynamic model; (iii) the development of a mechanistic-based model to bridge between patients and healthy volunteers; and (iv) propagation of the stage III model to a large efficacy study. The analyses utilised available concentration measurements (stages I–IV), CD11b receptor occupancy data (stages I–III) and neutrophil count data (stages III–IV) from three healthy volunteers (study 1, n = 51; study 2, n = 31; study 4, n = 15) and two patient studies (study 3, n = 169; study 5, n = 992). In studies 1–4, subjects received placebo or between three and six doses of UK-279,276 covering a range of 0.006 and 1.5 mg/kg as a single 15-minute intravenous infusion. In study 5, subjects received placebo or one of 15 possible doses of UK-279,276 (10–20mg) assigned through adaptive design and administered as a single 15-minute intravenous infusion. All model building was conducted using NONMEM version VI (beta).
The empirical pharmacokinetic/pharmacodynamic model developed during stage I was used to demonstrate that the pharmacokinetic assay was measuring biologically active drug. Simulations from the stage II model, developed from study 3, were used in the design of study 5. The model supported the switch to a fixed-dose regimen and the selection of the maximum dose and dosage increments. The common mechanistic-based model developed during stage III was used to support the ‘comparability strategy’ for UK-279,276 and provided insight into the underlying clearance mechanisms. At stage 4, the prior functionality available with NONMEM was used to successfully propagate the model from stage III in order to analyse the pharmacokinetic data from study 5. The analysis indicated that the exposure in study 5 was consistent with prior data. The role of empirical-based models in providing the learning for future mechanistic model development was highlighted. Similarly, the qualitative and quantitative aspects to knowledge propagation and the ultimate benefits from the development of the mechanistic-based model were demonstrated.
While the empirical-based models were used to guide some early drug development decisions for UK-279,276, the development of the mechanistic-based model was valuable in linking the complex pharmacokinetics/pharmacodynamics of UK-279,276 across the phases of drug development.
Similar content being viewed by others
References
Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61(3): 275–91
Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67–95
Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8(3): 183–93
Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111(1): 98–111
Mazzoni MC, Schmid-Schonbein GW. Mechanisms and consequences of cell activation in the microcirculation. Cardiovasc Res 1996; 32(4): 709–19
Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320(6): 365–76
Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 1998; 788(1–2): 25–34
Moyle M, Foster DL, McGrath DE, et al. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. J Biol Chem 1994; 269(13): 10008–15
Krams M, Lees KR, Hacke W, et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34(11): 2543–8
Jonsson EN, McIntyre F, James I, et al. Bridging PK/PD across healthy volunteers and patients using mechanistically based models. Pharm Res 2005; 22(8): 1236–46
Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Phamacokinet Pharmacodyn 2002; 29(5/6): 473–505
Lees KR, Diener HC, Asplund K, et al. UK-279-276, a neutrophil inhibitory glycoprotein, in acute stroke. Stroke 2003; 34: 1704–9
Berry DA, Mueller P, Grieve AP, et al. Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Kass RE, Carlin B, et al., editors. Studies in Bayesian statistics. Vol 5. New York: Springer-Verlag, 2002: 99–181
Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999; 27(4): 397–420
Bowen JD, Petersdorf SH, Richards TL, et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998; 64(3): 339–46
Simon DI, Ezratty AM, Francis SA, et al. Fibrin (ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993; 82(8): 2414–22
Walker RI, Willemze R. Neutrophil kinetics and the regulation of granulopoiesis. Rev Infect Dis 1980; 2(2): 282–92
Jagels MA, Hugh TE. Mechanisms and mediators of neutrophilic leukocytosis. Immunopharmacology 1994; 28(1): 1–18
Kato H, Kogure K, Liu XH, et al. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res 1996; 734(1–2): 203–12
Webster R, Phipps J, Hyland R, et al. Evaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor). Xenobiotica 2003; 33(9): 945–56
Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20(24): 4713–21
Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998; 15(9): 1463–8
Lunn DJ, Best N, Thomas A, et al. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 2002; 29(3): 271–307
Arlington S. Pharma 2005: an industrial revolution in R&D: Somers (NY): PriceWaterhouseCoopers, 1998
Arlington S. Pharma 2005 silicon rally: the race to e-R&D: Somers (NY): PriceWarterhouseCoopers, 1999
Arlington S. Pharma 2010: the threshold of innovation: Somers (NY): IBM Business Consulting Services, 2003
Acknowledgements
This work was sponsored by Pfizer Global Research and Development, Sandwich, UK, and the Swedish Foundation for Strategic Research, Stockholm, Sweden. Drs Marshall, Macintyre, James and Krams are employees of Pfizer, Inc., and Dr Jonsson was an employee at the University of Uppsala when this work was performed but is presently working at Roche Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marshall, S., Macintyre, F., James, I. et al. Role of Mechanistically-Based Pharmacokinetic/Pharmacodynamic Models in Drug Development. Clin Pharmacokinet 45, 177–197 (2006). https://doi.org/10.2165/00003088-200645020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200645020-00004